| 23rd Dec 2019 7:00 am |
RNS |
Triple-combination approved in China for COPD |
| 23rd Dec 2019 7:00 am |
RNS |
Enhertu (trastuzumab deruxtecan) approved in US |
| 20th Dec 2019 7:00 am |
RNS |
AstraZeneca divests rights to Arimidex and Casodex |
| 17th Dec 2019 6:06 pm |
RNS |
FDA panel backs Lynparza use for pancreatic cancer |
| 16th Dec 2019 7:00 am |
RNS |
Seroquel rights agreement complete: Europe, Russia |
| 12th Dec 2019 7:00 am |
RNS |
Imfinzi approved in China for Stage III NSCLC |
| 11th Dec 2019 1:00 pm |
RNS |
Trastuzumab deruxtecan achieves ORR of 60.9% |
| 5th Dec 2019 7:00 am |
RNS |
Lynparza approved in China for 1L BRCAm ovarian |
| 3rd Dec 2019 7:00 am |
RNS |
AstraZeneca divests Seroquel rights: US and Canada |
| 2nd Dec 2019 3:00 pm |
RNS |
Block listing Interim Review |
| 2nd Dec 2019 3:00 pm |
RNS |
Total Voting Rights |
| 29th Nov 2019 7:00 am |
RNS |
Imfinzi granted FDA Priority Review for SCLC |
| 21st Nov 2019 6:15 pm |
RNS |
Calquence approved in CLL in the US |
| 15th Nov 2019 7:00 am |
RNS |
Qtrilmet approved in the EU for treatment of T2D |
| 14th Nov 2019 7:00 am |
RNS |
FDA accepts regulatory submission for selumetinib |
| 12th Nov 2019 7:00 am |
RNS |
Anifrolumab demonstrated superiority in TULIP 2 |
| 11th Nov 2019 7:00 am |
RNS |
Roxadustat pooled analyses: no increased CV risk |
| 8th Nov 2019 7:00 am |
RNS |
Roxadustat significantly increased haemoglobin |
| 6th Nov 2019 2:10 pm |
RNS |
Calquence data to show improved progression-free |
| 1st Nov 2019 3:00 pm |
RNS |
Total Voting Rights |
| 30th Oct 2019 7:00 am |
RNS |
AstraZeneca divests rights to Seroquel and |
| 28th Oct 2019 3:31 pm |
RNS |
Imfinzi and Imfinzi plus tremelimumab delayed |
| 24th Oct 2019 7:00 am |
RNS |
AstraZeneca year-to-date and Q3 2019 results |
| 21st Oct 2019 7:00 am |
RNS |
Farxiga approved in the US to reduce the risk of |
| 17th Oct 2019 7:00 am |
RNS |
Trastuzumab deruxtecan granted FDA Priority Review |
| 4th Oct 2019 3:04 pm |
RNS |
Holding(s) in Company |
| 4th Oct 2019 3:00 pm |
RNS |
Holding(s) in Company |
| 4th Oct 2019 7:00 am |
RNS |
Fasenra approved in the US for self-administration |
| 3rd Oct 2019 4:00 pm |
RNS |
Director Declaration |
| 1st Oct 2019 3:00 pm |
RNS |
Total Voting Rights |
| 1st Oct 2019 7:05 am |
RNS |
AstraZeneca divests rights for Losec to Cheplaphar |
| 1st Oct 2019 7:00 am |
RNS |
Update on US regulatory review of PT010 in COPD |
| 30th Sep 2019 3:30 pm |
RNS |
Lynparza more than doubled the time without |
| 30th Sep 2019 7:00 am |
RNS |
Tagrisso is the only 1st-line treatment for EGFR- |
| 30th Sep 2019 7:00 am |
RNS |
Lynparza improved the time women lived without |
| 23rd Sep 2019 7:00 am |
RNS |
Qtrilmet recommended for approval in EU by CHMP |
| 18th Sep 2019 7:00 am |
RNS |
AstraZeneca amends collaboration with Ironwood |
| 9th Sep 2019 8:38 am |
RNS |
Imfinzi is first immunotherapy to show both |
| 4th Sep 2019 7:11 am |
RNS |
Tagrisso approved in China as a 1st-line treatment |
| 2nd Sep 2019 3:00 pm |
RNS |
Total Voting Rights |
